Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results for 2019
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Bristol-Myers Squibb (BMY) Tops Q4 EPS by 28c, Offers FY Guidance, Approves $5B Buyback
February 6, 2020 7:08 AM ESTBristol-Myers Squibb (NYSE: BMY) reported Q4 EPS of $1.22, $0.28 better than the analyst estimate of $0.94. Revenue for the quarter came in at $7.9 billion versus the consensus estimate of $6.19 billion.
Bristol-Myers Squibb maintains a balanced approach to capital allocation focused on future business development and sourcing external innovation as a priority, de-leveraging in the near term to maintain strong investment grade credit ratings and less than 1.5x debt/EBITDA by 2023, planning for annual dividend increases, subject to board... More
